Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Renabio Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and 1 distinct art unit. This indicates a highly focused prosecution state where all of the company's current activity is centered on a single matter. The presence of only 1 distinct art unit suggests that the technology currently under review falls within a specific niche of the Biotechnology & Pharmaceuticals sector.
JOHNSON, ALLISON MARIE is the busiest examiner for this company. This examiner is responsible for 1 busiest examiner pending office action, which is the only active action for the portfolio. Because there is 1 distinct examiner, the prosecution process is centralized with a single official. The relationship between the 1 pending office action and the 1 distinct examiner simplifies the administrative tracking of this portfolio while focusing all current efforts on a single proceeding. This assignment ensures that all communication is directed through JOHNSON, ALLISON MARIE within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | 1638 | §102Other | Non-Final OA | — | Pending | Jan 14, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRenabio Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Allison Marie Johnson has the most, with 1 of Renabio Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
